Extended indication Extension of indication to include treatment of adults and adolescents (aged 12 years and older weig
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Tixagevimab / cilgavimab
Domain Infectious diseases
Reason of inclusion Indication extension
Main indication COVID-19
Extended indication Extension of indication to include treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID-19, who do not require supplemental oxygen.
Proprietary name Evusheld
Manufacturer AstraZeneca
Route of administration Intramuscular
Therapeutical formulation Injection

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date May 2022
Expected Registration March 2023
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.